Drug
Vay736 Lower Dose
Vay736 Lower Dose: highest development phase Phase 1/2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1/2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| VAY736 lower dose NCT02495129 | Phase 1/2 | Primary Sjögren's Syndrome |
Latest
No recent events.
Follow Vay736 Lower Dose on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.